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An atlas of polygenic risk score
associations to highlight putative causal
relationships across the human phenome
Tom G Richardson*, Sean Harrison, Gibran Hemani, George Davey Smith
MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol
Medical School, University of Bristol, Bristol, United Kingdom
Abstract The age of large-scale genome-wide association studies (GWAS) has provided us with
an unprecedented opportunity to evaluate the genetic liability of complex disease using polygenic
risk scores (PRS). In this study, we have analysed 162 PRS (p<510 05) derived from GWAS and
551 heritable traits from the UK Biobank study (N = 334,398). Findings can be investigated using a
web application (http://mrcieu.mrsoftware.org/PRS_atlas/), which we envisage will help uncover
both known and novel mechanisms which contribute towards disease susceptibility. To
demonstrate this, we have investigated the results from a phenome-wide evaluation of
schizophrenia genetic liability. Amongst findings were inverse associations with measures of
cognitive function which extensive follow-up analyses using Mendelian randomization (MR)
provided evidence of a causal relationship. We have also investigated the effect of multiple risk
factors on disease using mediation and multivariable MR frameworks. Our atlas provides a resource
for future endeavours seeking to unravel the causal determinants of complex disease.
DOI: https://doi.org/10.7554/eLife.43657.001
Introduction
Developing our understanding of how modifiable social, behavioural and physiological factors influ-
ence risk of disease is of vital importance to improve effective medical treatment and preventative
interventions (Abraham et al., 2016). Genetic factors may also contribute substantially to disease
susceptibility, as demonstrated by recent large-scale genome-wide association studies (GWAS)
which have uncovered thousands of trait-associated single nucleotide polymorphisms (SNPs)
throughout the human genome. However, typically the magnitude of effect and variance explained
by one of these common genetic variants is small (Visscher et al., 2017). Polygenic risk scores (PRS),
commonly defined as the sum of trait-associated SNPs weighted by their effect sizes, harness find-
ings from GWAS to provide an overall measure of an individual’s genetic liability to develop disease
(Torkamani et al., 2018). Although early applications of PRS were found to be underwhelming in
terms of disease prediction (Ripatti et al., 2010), breakthroughs in the scale of GWAS and accessi-
bility to biobank scale datasets have substantially improved their performance (Khera et al., 2018;
Lee et al., 2018). As such, they hold considerable potential to improve early disease prognosis and
treatment plan formulation (Lewis and Vassos, 2017).
Along with the emerging utility of PRS to predict disease, they have also been previously used to
evaluate putative causal relationships (Davies et al., 2018; Palmer et al., 2012). For example,
instead of using a coronary heart disease (CHD) PRS to predict incidence of this disease, studies
have investigated whether scores for known risk factors, such cholesterol and lipid levels
(Holmes et al., 2015), are also strongly associated with CHD incidence. One such approach in this
paradigm is Mendelian randomization (MR), a method by which genetic variants are leveraged as
instrumental variables to investigate causal relationships between modifiable risk factors and disease
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outcomes (Davey Smith and Ebrahim, 2003; Davey Smith and Hemani, 2014). MR is typically lim-
ited to using SNPs which survive conventional GWAS corrections (i.e. p<510 08), which may lack
statistical power if these variants do not explain a large proportion of trait variance. In contrast, PRS
derived using a more lenient threshold (e.g. p<510 05) can help recover some of this missing heri-
tability due to a larger number of SNPs being included. This may help improve detection rates for
causal relationships, which can be particularly useful when evaluating associations between genetic
liability for a given trait and hundreds of diverse health outcomes. Such endeavours are commonly
referred to as phenome-wide association studies (Denny et al., 2013; Fritsche et al., 2018;
Krapohl et al., 2016; Millard et al., 2015).
To investigate this we undertook a preliminary simulation study to compare the performance of
using a PRS to detect causal relationships with a popular MR approach (the inverse variance
weighted (IVW) method (Burgess et al., 2013)) (Figure 1). Results indicated that, although using a
PRS provides higher statistical power, it also suffers from substantive false positive rates due to hori-
zontal pleiotropy, the phenomenon whereby a gene influences multiple traits via independent bio-
logical pathways (Davey Smith and Hemani, 2014). SNPs which are known to be pleiotropic with
large effects on different and diverse traits have been found to distort findings from PRS analyses
(Felsky et al., 2018). As a consequence, findings from phenome-wide association studies using a
PRS may be useful in terms of highlighting putative causal associations, although robust evaluations
are necessary to investigate results. We therefore propose using various sensitivity analyses devel-
oped in the field of MR to discern whether PRS associations represent causal relationships or not. To
facilitate such future analyses, an accessible resource to evaluate associations between disease
genetic liability and complex traits from across the human phenome should prove to be of consider-
able value.
In this study, we have constructed 162 different PRS (based on p<510 05) using findings from
large-scale GWAS and evaluated their association with 551 traits in up to 334,398 individuals
enrolled in the UK Biobank study (Bycroft et al., 2018; Sudlow et al., 2015). To disseminate these
findings, we have developed a web application to examine and visualise this derived atlas of
eLife digest An individual’s risk of developing many diseases, including heart disease and
schizophrenia, is influenced by a complex combination of lifestyle factors and the genes they inherit
at birth. The total number of genetic variants that an individual has that increases their risk of
developing a particular disease can be measured as their ‘polygenic risk score’. These scores allow
researchers to predict whether it is likely that someone will develop a disease during their lifetime.
Polygenic risk scores can also be used to link different conditions or traits to each other. For
example, if high blood pressure can be caused by obesity, then genetic variants linked to obesity
will also influence blood pressure. As a result, individuals with a high polygenic risk score for obesity
will, on average, have a higher blood pressure than those with a low score. Comparing associations
between polygenic risk scores and traits can therefore suggest whether one trait causes another.
Richardson et al. have developed an ‘atlas’ that uses data from the UK Biobank study – which
contains genetic data from over 300,000 people – to investigate how shared characteristics and risk
factors in individuals relate to their genetic likelihood of developing a disease. The data currently
includes 162 different polygenic risk scores and 551 traits.
Richardson et al. used the atlas to evaluate which traits are most strongly linked to the polygenic
risk score for schizophrenia. Analyses of these traits suggested that individuals with a high genetic
risk of developing schizophrenia tend to perform worse in IQ and short-term memory tests, and that
they are less likely to successfully quit smoking. These characteristics have previously been observed
in studies of individuals with schizophrenia.
In the future, the atlas could be used to identify possible relationships between a wide range of
individual traits and diseases. This could help to prioritise which relationships should be investigated
further as part of studies to understand the causes and consequences of disease. In the long term,
such studies should improve our ability to prevent and treat many different medical conditions.
DOI: https://doi.org/10.7554/eLife.43657.002
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associations. We have also undertaken follow-up analyses to demonstrate the usefulness of this
resource to help identify putative causal relationships. Firstly, we have interpreted findings from a
hypothesis-free scan of associations between the schizophrenia PRS and each of the 551 traits. We
demonstrate that amongst these findings are associations which may likely reflect underlying causal
relationships. We have also showcased the utility of evaluating the association between all 162 PRS
and a single outcome using our atlas. Using gout susceptibility as an example, we demonstrate how
recently developed methodology (mediation MR and multivariable MR) can be applied to evaluate
the effects of multiple risk factors on disease risk.
Results
An atlas of polygenic risk score associations across the human phenome
Overall, we undertook 89,262 tests to investigate the association between 162 different PRS derived
from GWAS (Supplementary file 1a) and 551 complex traits from the UK Biobank study
(Supplementary file 1b). PRS were constructed using independent SNPs for each GWAS
(p<510 05) based on r2< 0.001 using genotype data from European individuals (CEU) from phase
3 (version 5) of the 1000 Genomes project (Abecasis et al., 2012). As opposed to the conventional
GWAS cut-off of p<510 08, the threshold of p<510 05 was selected to incorporate additional
SNPs into scores which may explain additional heritability for GWAS traits. Furthermore, this allowed
us to create PRS for traits which had no SNPs surviving conventional GWAS corrections, as well as
increasing the number of SNPs used in scores for traits with only a small number of GWAS hits. Our
final sample size for analysis consisted of 334,398 individuals. This was determined using a strict
exclusion criterion to reduce false positive associations, removing individuals with withdrawn con-
sent, evidence of genetic relatedness or who were not of ‘white European ancestry’ based on a
K-means clustering (K = 4).
Of the 162 GWAS we identified, 11 reported that they included UK Biobank participants in their
analysis. As this may lead to overfitting, the PRS for these 11 traits were not weighted to reduce this
source of bias. To demonstrate this, we evaluated the association of the sleep duration PRS in the
UK Biobank study, weighting SNPs based on a GWAS involving the interim release of this dataset
(Jones et al., 2016) (Supplementary file 1c). However, this only mitigates this limitation, and as
such these scores in particular require extensive follow-up analyses. In case they are still useful for
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Figure 1. A comparison of the performance between the inverse variance weighted (IVW) Mendelian randomization (MR) model against polygenic risk
score (PRS) analysis. Simulations were conducted under different levels of horizontal pleiotropy for two different models; the causal model (where the
simulated exposure has a causal effect on the outcome) and the null model (where there is no causal effect between exposure and outcome).
DOI: https://doi.org/10.7554/eLife.43657.003
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follow-up analyses despite overlapping with UK Biobank, these scores have been clearly flagged in
Supplementary file 1a by being allocated to the ‘unweighted’ subcategory.
In this study we have only interpreted findings from associations with PRS derived using the
p<510 05 threshold. However, analyses have been repeated using scores derived using the con-
ventional GWAS threshold of p<510 08 for future studies that wish to evaluate these results. Com-
plex traits from the UK Biobank study were selected based on p<0.05 from previously undertaken
heritability analyses within this study (Neale Lab, 2017). This threshold was chosen as a heuristic to
highlight associations worth pursuing in further detail. A web app to query and visualise these results
can be found at http://mrcieu.mrsoftware.org/PRS_atlas/.
Stratifying the UK Biobank sample into deciles based on their PRS supported previous findings in
the literature demonstrating the ability of PRS to predict risk of disease. For example, comparing
the highest and lowest deciles of the coronary heart disease (CHD) PRS found that individuals had
increased odds of 3.64 to develop this disease (based on the ICD10 code ‘I25’). A recent study by
Khera and colleagues (Khera et al., 2018) reported a similar odds ratio for CHD in their analysis
(OR:>3.0 for the highest 8% of individuals based on their PRS). However, we note that they identi-
fied a higher area under curve in their analysis (0.806), which is likely attributed to tuning parameters
such as LD clumping, along with covariates adjusted for in their analysis.
Combining this PRS with scores for established causal risk factors for CHD suggested that they
can help improve polygenic prediction (namely low density lipoprotein (LDL) cholesterol and myocar-
dial infarction), although integrating any associated scores in a hypothesis-free manner may hinder
prediction (Figure 2). This could potentially due to the increase in variance incorporated into predic-
tion analyses from scores that do not directly influence CHD, or alternatively may indicate that they
are spurious associations. Additional research is required to evaluate the contribution of multiple
PRS as predictors of a single outcome. Doing so may help develop a greater understanding regard-
ing which traits can help predict disease outcomes using PRS.
Amongst other findings, we observed that participants had increased odds of 2.43 in terms of
obtaining a University or College degree when comparing top and bottom deciles for the years of
schooling PRS. Other noteworthy examples included a 3.48 fold increase in odds of taking atorvasta-
tin as medication when comparing the extreme deciles for the LDL PRS. We also observed that par-
ticipants in the highest decile for the ulcerative colitis PRS had increased odds of 5.36 in terms of
developing this disease in comparison to those in the lowest decile (based on the ICD10 code
‘K51’).
Uncovering known and novel findings by conducting a phenome-wide
evaluation of associations
To demonstrate the value of this atlas of results, we have investigated some of the strongest associa-
tions detected between the schizophrenia PRS and all 551 complex traits analysed in the UK Biobank
study (Figure 3, Supplementary file 1d). Associations within our atlas could potentially be identified
due to underlying epidemiological relationships, although there are various other possible explana-
tions such as a shared genetic aetiology between traits. To investigate this for our associations with
the schizophrenia PRS, we have used various methods in two-sample MR as an example of how
future studies could evaluate findings from our atlas. For these analyses we only used SNPs with
p<510 08 as instrumental variables to reduce the likelihood of weak instrument bias in our analysis
(Davies et al., 2015). Furthermore, in these analyses we model liability to schizophrenia as our expo-
sure within an MR framework with associated complex traits as outcomes (unless stated otherwise).
Our systematic approach involved the following:
1. As an initial evaluation, we investigated evidence of association using the inverse variance
weighted (IVW) (Burgess et al., 2013) method and derived Cochran’s Q statistic as an indica-
tor of potential heterogeneity. Weak evidence of association in this analysis suggests that a
causal effect is unlikely.
2. If the IVW method provides strong evidence of association but in the presence of heterogene-
ity, we suggest undertaking two additional MR analyses using the weighted mode
(Hartwig et al., 2017) and weighed median (Bowden et al., 2016) methods. If there is a lack
of strong evidence in both of these analyses then associations are unlikely to be causal.
3. As a sensitivity analysis, repeat steps 1 and 2 but only using SNPs as instruments which are not
filtered out by applying the MR directionality test (Hemani et al., 2017). We also recommend
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evaluating the MR-Egger intercept term (Bowden et al., 2015) to discern whether estimates
may be biased by directional pleiotropic effects.
The top association with the schizophrenia PRS suggests that individuals with high schizophrenia
genetic liability have increased odds of seeing a psychiatrist at some point in their lives due to
nerves, anxiety, tension of depression (OR = 1.09 per standard deviation increase in PRS, 95%
CI = 1.08 to 1.10, p=1.5510 50). The schizophrenia PRS was also strongly associated with various
neurological traits, such as neuroticism (Beta = 0.066, SE = 0.006, p=8.1710 27), being ‘tense or
highly strung’ (OR = 1.07, 95% CI = 1.07 to 1.08, p=2.2510 47) and self-reported depression
(OR = 1.07, 95% CI = 1.06 to 1.08, p=4.9110 18).
We identified strong evidence that schizophrenia genetic liability influences this set of neurologi-
cal traits (Supplementary file 1e), except for self-reported depression where strong evidence was
only detected using the inverse variance weighted (IVW) method (Beta = 0.004, SE = 0.001,
Figure 2. A receiver operator curve for ischaemic heart disease polygenic prediction. A receiver operating characteristic (ROC) curve to compare the
sensitivity and specificity of polygenic risk scores (PRS) and individuals with ischaemic heart disease (defined using ICD 10 codes ‘I25’) in the UK Biobank
study. The scores evaluated were 1. Coronary Heart Disease (CHD), 2. A combined scored of CHD, Myocardial Infarction (MI) and Low Density
Lipoprotein cholesterol (LDL), 3. All traits with a p-value<110 06 in our PRS analysis (excluding scores from GWAS overlapping with the UK Biobank
sample). These were CHD, MI, LDL, Total cholesterol, Triglycerides, High Density Lipoprotein cholesterol, Years of schooling, Height and Waist
Circumference. All PRS were constructed from GWAS using independent SNPs with p<510 05.
DOI: https://doi.org/10.7554/eLife.43657.004
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p=0.009). There was also no strong evidence of directional horizontal pleiotropy for these results
based on the MR Egger intercept term and associations were detected after repeating analyses
using MR directionality filtering.
Along with using MR to investigate the effect of PRS traits on outcomes, we recommend investi-
gating the converse direction of effect where possible (also known as ‘bi-directional’ MR
(Timpson et al., 2011). For example, for the associations detected with the schizophrenia PRS, asso-
ciated traits in the UK Biobank were modelled as our exposure in an MR setting and schizophrenia
was treated as our outcome. Results suggested that neuroticism liability influences schizophrenia risk
(Supplementary file 1f), although we detected evidence of directional horizontal pleiotropy based
on the MR Egger intercept term (Beta = 0.043, SE = 0.018, p=0.018). After applying MR directional-
ity filtering, we also identified evidence of association between being ‘tense or highly strung’ and
schizophrenia risk. Therefore, the most parsimonious explanation for these findings could be that
they have been observed due to a shared genetic aetiology between schizophrenia and other neuro-
logical traits. This is also likely to be a plausible explanation for other associations within our atlas. In
particular, caution is advised when interpreting findings between autoimmune traits which are known
to be influenced by highly correlated genes residing in the HLA region of the genome (Gough and
Simmonds, 2007). Although these findings could still be of interest in terms of genetic correlations
between traits, they may not reflect underlying causal relationships (O’Connor and Price, 2018).
Amongst other findings, there were associations which suggested individuals with high schizo-
phrenia genetic liability had a lower fluid intelligence score (Beta =  0.083, SE = 0.006,
p=1.4910 39). We also observed evidence that these individuals performed worse than others in
an assessment of cognitive function concerning memorising pairs of cards (Beta = 0.020, SE = 0.002,
p=6.6610 34 for ‘number of incorrect matches’). Follow-up MR analyses provided evidence from
Figure 3. A bi-directional phenome-wide association plot for schizophrenia genetic liability. Each point on this plot represents the association between
the schizophrenia polygenic risk score (based on p<510 05) and a complex trait in the UK Biobank study. Along the y-axis are –log10 p-values for
these associations multiplied by the direction of effect for their corresponding effect size. As such, traits positively associated with schizophrenia
genetic liability reside above the horizontal grey line representing the null (i.e. –log10 (P) = 0), whereas negative associations are below. Points are
grouped and coloured based on their corresponding complex traits’ subcategory. Horizontal red lines indicate the Bonferroni corrected threshold for
the 551 tests undertaken (i.e. 0.05/551 = 9.0710 05).
DOI: https://doi.org/10.7554/eLife.43657.005
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multiple methods that schizophrenia genetic liability (i.e. our exposure) influences both of these out-
comes (Supplementary file 1g). These results were robust to sensitivity analyses using MR direction-
ality filtering and MR Egger intercepts did not indicate that findings were prone to directional
horizontal pleiotropy. In contrast, we did not detect strong evidence of a causal effect in the oppo-
site direction for these associations (i.e. evaluating the effect on measures of cognition and memory
on schizophrenia risk), in particular after applying MR directionality filtering and when evaluating
results from the weighted median and mode methods (Supplementary file 1h). We also conducted
a leave-one out analysis which suggested that no individual SNPs were responsible for driving
observed effects (Appendix 1—Figure 1, Appendix 1—Figure 2). Taken together, these analyses
support evidence that schizophrenia genetic liability may lead to reduced cognitive function.
Elsewhere, there were associations indicating that participants with a high schizophrenia PRS
were more likely to be unsuccessful when attempting to quit smoking (Beta = 0.028, SE = 0.003,
p=3.8710 22) and, accordingly reduced odds of being a past smoker (OR = 0.97, 95% CI = 0.97 to
0.98, p=9.7110 17). We observed strong evidence of association that schizophrenia genetic liability
influences these outcomes (Supplementary file 1i), whereas the converse direction of effect pro-
vided weak evidence of an effect (Supplementary file 1j). However, the ‘number of unsuccessful
smoking attempts’ outcome could only be instrumented using a single variant which limits our ability
to investigate this effect. Moreover, a recent study has uncovered a large number of SNPs robustly
associated with smoking cessation and provided evidence of a bi-directional relationship between
smoking and schizophrenia using MR (Wootton, 2018). Leave-one out analyses suggested that no
individual SNP was responsible for driving observed associations (Appendix 1—Figure 3, Appen-
dix 1—Figure 4).
We also observed a strong inverse association between the schizophrenia PRS and various
anthropometric traits. However, evaluating the relationship between schizophrenia liability and body
mass index (BMI) provided weak evidence of a causal effect in both directions (Supplementary files
1k & 1l). This result reinforces our recommendation that all findings within our atlas require in-depth
evaluation to discern whether they represent potential causal associations.
Elucidating risk factors which may play a mediating role along the
causal pathway to disease
Another strength of our atlas is that findings can be evaluated by selecting an outcome of interest
and evaluating which of the 162 PRS are most strong associated with it. Doing so may motivate
future endeavours to investigate the effect of multiple risk factors on disease risk. As a demonstra-
tion of this, we have evaluated the associations between all PRS and self-reported gout in the UK
Biobank study (Supplementary file 1m). In this analysis, there was strong evidence of association
using the PRS for gout itself (OR = 1.16, 95% CI = 1.13 to 1.19), although we also observed a much
larger magnitude of effect using the urate PRS (OR = 1.75, 95% CI = 1.72 to 1.78). Although many
of the PRS in our analysis may be the best polygenic predictors for their target disease/trait, there
may be other examples similar to this where the strongest association for an outcome is not the cor-
responding PRS. For example, the strongest association for birth weight as an outcome in our atlas
was with the height PRS (Beta = 0.080, SE = 0.002, p=1.3110-249).
A receiver operating characteristic plot (Figure 4) illustrates this point, where the area under
curve for the gout PRS was 0.54 in comparison to the urate PRS which had a value of 0.65. This may
be attributed to gout being a binary outcome heavily influenced by the number of cases analysed in
its corresponding GWAS (N = 2,115). In comparison, urate is a continuous trait measured in all par-
ticipants for its respective GWAS (N = 110,347). After urate, the next strongest positive associations
with self-reported gout were triglycerides (TG) and body mass index (BMI) (OR = 1.14, 95%
CI = 1.11 to 1.16 and OR = 1.09, 95% CI = 1.06 to 1.12 respectively). However, it is unclear whether
these risk factors influence gout risk independently of one and other or if they reside on the same
causal pathway to disease.
We investigated this by firstly using an MR mediation framework which involved evaluating bi-
directional relationships for each risk factor in turn. As before, only SNPs with p<510 08 for each
PRS were used as instrumental variables in MR analyses. There was strong evidence that BMI (i.e.
our exposure) had a causal effect on each other trait in turn (TG, urate and gout), where effect esti-
mates appeared to be consistent between different MR methods (Supplementary file 1n). Repeat-
ing this analysis for TG as our exposure provided evidence of a causal effect on urate and gout risk,
Richardson et al. eLife 2019;8:e43657. DOI: https://doi.org/10.7554/eLife.43657 7 of 24
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but not BMI (Supplementary file 1o). We then modelled urate as our exposure variable, which sug-
gested that increased urate positively influences gout risk, although there was weak evidence of an
effect on either BMI or TG (Supplementary file 1p). In all analyses there was no strong evidence of
horizontal pleiotropy based on the MR-Egger intercept terms and findings were robust to sensitivity
analyses using MR directionality filtering (Supplementary file 1n-1p). We also undertook leave-one
out analyses which found that no single SNP was driving observed effects (Appendix 1—Figure 5,
Appendix 1—Figure 6, Appendix 1—Figure 7, Appendix 1—Figure 8). In conclusion, as illustrated
in Figure 5a, findings from the mediation MR analysis suggests that BMI influences TG levels
(Figure 5a (1)), which has an effect of urate (Figure 5a (2)), and this subsequently influences gout
risk (Figure 5a (3)). Using the effect estimates from our IVW analysis, we estimated that 77% of the
overall effect of BMI on gout risk (Figure 5a (4)) is mediated through this causal pathway.
We also used a related approach to investigate the effect of these multiple risk factors on gout
susceptibility, known as multivariable MR (Sanderson et al., 2018). In this analysis genetic instru-
ments for all exposures (i.e. BMI, TG and urate) are modelled simultaneously to investigate whether
these risk factors influence our outcome (i.e. gout) independently of one and other. We observed
Figure 4. A receiver operator curve for gout polygenic prediction. A receiver operating characteristic (ROC) curve to compare the sensitivity and
specificity of polygenic risk scores (PRS) and individuals with self-reported gout in the UK Biobank study. The scores evaluated were gout and urate
using independent SNPs identified by GWAS with p<510-05.
DOI: https://doi.org/10.7554/eLife.43657.006
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the effects of BMI and TG on gout risk attenuate when analysed in the same model as urate
(Supplementary file 1q). Furthermore, in subsequent analyses we applied multivariable MR to inves-
tigate each pairwise combination of these risk factors on gout risk. There was evidence of an attenu-
ation of the effect of BMI on gout risk when accounting for either the TG or urate effect
(Supplementary files 1r and 1s). We also observed the effect of TG on gout risk attenuate when
accounting for urate levels (Supplementary file 1t). These findings therefore support the same
direction of effect observed using the mediation framework (Figure 5b).
All Genetic
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Confounders
Body Mass Index Triglycerides Urate
Body Mass Index
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b) 
21
4
Gout
Urate  
Instruments
Triglycerides
3
Figure 5. Applying (a) mediation and (b) multivariable Mendelian randomization investigate the causal effect of body mass index, triglycerides and
urate on gout risk. (a) Mediation Mendelian randomization (MR) framework to investigate whether urate mediates the effect of body mass index (BMI)
and triglycerides (TG) on gout risk. The various analyses undertaken suggest that 1) elevated BMI increases TG levels 2) which subsequently has an
effect on urate 3) and this in turn influences gout risk. This mediation pathway may help explain the manner by which BMI, potentially driven by lifestyle
factors such as diet, is a risk factor for gout. (b) Multivariable MR framework attempting to reproduce findings from the mediation analysis. Genetic
instruments for BMI, TG and urate were analysed simultaneously to evaluate the joint effect of these risk factors on gout risk. The effect of BMI and TG
on gout risk attenuated compared to univariable analyses, suggesting that they influence gout risk through increased urate levels. Investigating each
combination of pairwise risk factors using this framework suggested that BMI influences TG rather than the opposite direction of effect, which also
supports findings from the mediation analysis.
DOI: https://doi.org/10.7554/eLife.43657.007
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Discussion
In this study we have developed an atlas of associations between PRS and complex traits across the
human phenome. Along with contributing to mounting evidence that PRS can be valuable in predict-
ing later life disease outcomes, we have provided examples of how this resource can be harnessed
to help identify potential risk factors in disease which warrant further investigation. We envisage that
the inferences we have made in this study are just the beginning of potential findings which can be
uncovered using such catalogues of associations. Multiple lines of evidence from robust follow-up
studies of putative causal risk factors will help improve our understanding of disease susceptibility
(Munafo` and Davey Smith, 2018).
Large-scale biobank datasets provide an unparalleled opportunity to undertake hypothesis-free
causal inference. Such efforts can help identify evidence supporting established causal relationships,
as well as potentially implicating novel ones (Davey Smith and Hemani, 2014; Cai et al., 2018). We
have illustrated this approach in our study by evaluating the results of a phenome-wide association
study of schizophrenia genetic liability. This identified strong associations with measures of cognitive
function and smoking behaviour which MR follow-up analyses suggested may be due to putative
causal relationships with schizophrenia genetic liability.
There is long standing evidence from the literature that cognitive impairment is a recognised
characteristic of schizophrenia (Mohamed et al., 1999). Although PRS may prove useful in determin-
ing lifelong risk of developing schizophrenia, based on currently available data they may be less
effective in terms of predicting age of schizophrenia onset as well as the severity of its progression.
Characterization of cognitive decline in individuals with a high schizophrenia PRS may therefore help
improve elucidation of its neurological basis, and ultimately improvement in therapeutic approaches
to it (Green, 1996).
There is also a wealth of evidence in the literature from observational studies that individuals
diagnosed with schizophrenia smoke more frequently compared to the general population
(Sacco et al., 2005). Our results indicate that UK Biobank participants with a high schizophrenia
genetic liability are more likely to be unsuccessful in their attempts to stop smoking. This may there-
fore suggest that the high frequency of schizophrenia patients who smoke could be attributed to
their inability to quit smoking. However, we were unable to support recent evidence which suggests
that smoking is a risk factor for schizophrenia which could be attributed to weak instruments in our
analysis (Wootton, 2018). The positive association with smoking behaviour may also provide a possi-
ble explanation for the inverse association we observed between schizophrenia genetic liability and
anthropometric traits.
In this study we have also provided an example of how investigating various PRS associations
with the same outcome may help motivate studies evaluating the effect of multiple risk factors on
disease risk. Our analysis detected evidence of an association between body mass index and gout
risk, putatively mediated by triglycerides and urate levels. The findings from this analysis therefore
appear to recapitulate known biology regarding the established causal pathway to gout
(Matsubara et al., 1989), (Li et al., 2017). Speculatively, a diet including high calorie and alcohol
consumption, which are known risk factors for increased body mass index and triglyceride levels,
may result in elevated circulating uric acid level and in turn increase gout risk. A recent study has
suggested that genetic factors may have a greater impact on serum urate levels than environmental
factors such as diet (Major et al., 2018). Our findings suggest that genetic drivers of appetite which
may influence higher BMI levels are likely to predominantly influence gout risk via increased urate
levels. We hope this illustration will motivate creative hypotheses for future endeavours to investi-
gate the effect of multiple risk factors on disease risk.
The application of PRS is a topic which has sparked considerable recent debate, particularly con-
cerning whether scores are relevant for clinical decision making (Warren, 2018). Although resources
such as the UK Biobank provide an unparalleled opportunity to investigate the determinants of com-
plex disease as we have done in this study, findings regarding genetic liability may not be generaliz-
able to individuals who are not of European descent. As such, there is likely to be an emphasis in the
forthcoming years on efforts to establish disease-specific datasets for a diverse range of ancestries.
We also note that, although we have adjusted all analyses in our study using the top 10 principal
components from the UK Biobank, there may still be an influence of geographic clustering which
remains unaccounted for Abdellaoui et al. (2018). Furthermore, although we have flagged the PRS
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traits in our study derived using GWAS which have overlapping samples with the UK Biobank, we
are unable to assess this for scores whose GWAS predate this cohort. Future efforts to link anony-
mous identifiers between the UK Biobank and UK cohorts would be of helpful in terms of ascertain-
ing this information to prevent overfitting. Lastly, certain complex traits in our study may benefit
from being combined to improve statistical power. For instance, a more powerful approach to iden-
tify associations between genetic liability and statin medication could involve deriving a combined
measure of all the different types of statins reported. Investigating these results in a hypothesis-free
manner as we have described in this study may also prove useful for drug repurposing efforts.
Polygenic risk scores hold huge promise in the era of large-scale genetic epidemiology to identify
individuals who are at high risk of disease. Associations detected between these scores and out-
comes undertaken by large-scale analyses should prove powerful for future studies that wish to
unravel causal relationships between complex traits. Doing so will help improve disease prevention
by developing a stronger understanding of complex epidemiological pathways.
Materials and methods
Simulations to compare polygenic risk score analysis with Mendelian
randomization
Our simulation study concerned two different models; the causal model (simulating a risk factor
which has a causal effect on the simulated outcome) and the null model (where there is no causal
effect between the simulated exposure and outcome). We ran 1000 simulations using each model to
compare the PRS approach with the IVW method using a dataset comprising of 10,000 samples and
50 SNPs. Further details and all the code used to conduct these simulations can be found at https://
github.com/explodecomputer/prs-vs-mr.
Constructing polygenic risk scores from large-scale genome-wide
association studies
We have used the MR-Base platform (Hemani et al., 2018) to identify SNPs from large-scale GWAS
to include in our PRS. Our inclusion criteria for selected GWAS was having a sample size of more
than 1000 participants, over 100,000 SNPs measured on genotyping arrays and based on European/
mixed populations. If multiple studies were found for the same trait, we selected the most recent
study or the one with the largest sample size.
PRS were constructed using SNPs for each GWAS trait based on p<510 05. A threshold of
r2 <0.001 was selected to identify independent SNPs using genotype data from European individuals
(CEU) from phase 3 (version 5) of the 1000 genomes project (Abecasis et al., 2012). When a GWAS
SNP was not available from the UK Biobank study genotype data, we used a proxy SNP instead
based on r2 0.8 using the same reference panel. Scores were then calculated as the sum of the
effect alleles for all SNPs weighted by their reported regression coefficients. However, a small subset
of PRS were left unweighted to reduce the likelihood of overfitting. This was due to their GWAS
including participants from the initial release of the UK Biobank study. As such, additional caution
should be exercised when interpreting findings from these unweighted PRS. Prior to analysis, each
PRS was normalised to have a mean of zero and a standard deviation (SD) of one. Our PRS construc-
tion pipeline was also applied using a more stringent threshold of p<510 08. Although we have
not interpreted any of the results using these more stringent scores in this report, they are available
within our atlas for future use.
Complex trait and genotype data from the UK Biobank study
We selected traits from the UK Biobank study (Sudlow et al., 2015) which had p<0.05 in the herita-
bility analyses conduct by the Neale lab (Neale Lab, 2017). Genotype data were available for
approximately 490,000 individuals enrolled in the study. Phasing and imputation of these data are
explained elsewhere (Bycroft et al., 2018). Individuals with withdrawn consent, evidence of genetic
relatedness or who were not of ‘white European ancestry’ based on a K-means clustering (K = 4)
were excluded from analysis. After exclusions there were up to 334,398 individuals with both geno-
type and complex trait data who were eligible for analysis.
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Statistical analysis
We evaluated the association between each combination of PRS and complex trait in the UK Bio-
bank study using linear regression (for continuous traits), logistic regression (for case/control traits),
ordinal logistic regression (for ordered categorical traits) and multinomial logistic regression (for
unordered categorical traits). All analyses were adjusted for age, sex, the first 10 genetic principle
components (to adjust for population stratification) and genotyping chip used to measure genetic
data in participants. Only female participants were included in the ‘Age at menarche’ and ‘Age at
menopause’ PRS analyses.
We also calculated R2 coefficients for continuous traits and McFadden pseudo R2 coefficients for
other models by repeating analyses unadjusted for covariates. McFadden’s R2 is defined as:
R2McF= 1 – ln(Lm/ln(L0)
where ln is the natural logarithm, L0 is the value of the likelihood function of the model with no pre-
dictors and Lm is the likelihood of the model being estimated. We note that pseudo R
2 coefficients
should not be interpreted in a similar manner to those derived using linear regression (Hu et al.,
2006).
Mendelian randomization analysis
We used various two-sample MR methods to evaluate associations detected in the PRS analysis. This
involved using the observed effects of the genetic variants used in the PRS on both the GWAS trait
that the score was based on (treated as the exposure in our MR analysis) as well as the UK Biobank
trait (treated as the outcome in our MR analysis). For all MR analyses we only selected SNPs with
p<510 08 based on GWAS findings as instrumental variables to reduce the likelihood of weak
instrument bias (Davies et al., 2015). In terms of MR methods, we applied the inverse variance
weighted (IVW) (Burgess et al., 2013), weighed median (Bowden et al., 2016) and weighted mode
approaches. We also conducted several different sensitivity analyses to evaluate findings. We
derived Cochran’s Q statistic when undertaking the IVW approach as an indicator of heterogeneity,
as well as repeating all analyses after filtering out SNPs which the MR directionality test suggested
did not influence the outcome of interest through the analysed exposure. The intercept of the MR-
Egger approach (Bowden et al., 2015) was used to investigate directional horizontal pleiotropy and
leave-one-out analyses (i.e. reapplying the IVW method after removing each SNP in turn with
replacement) were conducted to discern whether any individual SNPs were driving observed associa-
tions. These types of analyses are particularly important when assessing findings from our atlas, as
one possible explanation is that they could be attributed to a single pleiotropic SNP which has a
large effect size (e.g. the APOE locus which is associated with Alzheimer’s disease and lipid levels).
To investigate the direction of effect for associations identified in the PRS analysis we undertook
bi-directional MR (Timpson et al., 2011). This involves firstly modelling our PRS trait as our exposure
and complex trait as our outcome, and subsequently the complex trait as our exposure and PRS trait
as our outcome in a separate analysis. Lastly, we have incorporated two recent developments within
the field of MR; mediation MR and multivariable MR (Sanderson et al., 2018). These methods can
be used to investigate the effect of multiple risk factors on a single outcome, as well as uncover
potential mediators in disease. In this study we have evaluated findings from the PRS analysis based
on the p<510 05 threshold. We note however that it is only advisable to apply techniques in MR
using this threshold as long as in-depth sensitivity analyses (e.g. leave-one out, MR-Egger intercept)
are also undertaken to robustly evaluate findings.
When undertaking our example of mediation MR in this study, we also calculated the proportion
mediated along the causal pathway from exposure to outcome using effect estimates derived using
the IVW method, where:
Proportion mediated = direct effect   indirect effect
direct effect
The direct effect here is the IVW effect estimate derived for the association between the expo-
sure (i.e. BMI) and our outcome (i.e. gout). The indirect effect was calculated as the product of all
IVW effect estimates derived for all relationships along the causal pathway of interest (i.e. the effect
of BMI on triglycerides, the effect of triglycerides on urate and the effect of urate on gout).
All analyses were undertaken using R (version 3.5.1). The R package ‘shiny’ v1.1 was used to
develop the web application and ‘highcharter’ v0.5 was used to generate interactive plots. Figures
in this manuscript were generated using ‘ggplot2’ v2.2.1.
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Data availability
All summary statistics for the analyses undertaken in this study can be downloaded using our web
application (http://mrcieu.mrsoftware.org/PRS_atlas/). Our dataset was derived from the UK Biobank
study as part of projects 8786 and 15825. The same dataset can be created with an application to
use data from the UK Biobank study (http://biobank.ctsu.ox.ac.uk/crystal/).
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Appendix 1—figure 1. A plot illustrating a leave-one out analysis between schizophrenia
genetic liability and fluid intelligence.
DOI: https://doi.org/10.7554/eLife.43657.011
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Appendix 1—figure 2. A plot illustrating a leave-one out analysis between schizophrenia
genetic liability and ‘number of incorrect matches in a round’.
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Appendix 1—figure 3. A plot illustrating a leave-one out analysis between schizophrenia
genetic liability and ‘number of unsuccessful smoking attempts’.
DOI: https://doi.org/10.7554/eLife.43657.013
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Appendix 1—figure 4. A plot illustrating a leave-one out analysis between schizophrenia
genetic liability and past tobacco smoking.
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Appendix 1—figure 5. A plot illustrating a leave-one out analysis between body mass index
and triglycerides.
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Appendix 1—figure 6. A plot illustrating a leave-one out analysis between triglycerides and
urate.
DOI: https://doi.org/10.7554/eLife.43657.016
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Appendix 1—figure 7. A plot illustrating a leave-one out analysis between urate and gout.
DOI: https://doi.org/10.7554/eLife.43657.017
Richardson et al. eLife 2019;8:e43657. DOI: https://doi.org/10.7554/eLife.43657 23 of 24
Tools and resources Genetics and Genomics
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●All
rs6567160
rs943005
rs1016287
rs2060604
rs2112347
rs543874
rs3888190
rs11030104
rs6091540
rs7144011
rs12448257
rs17724992
rs17001654
rs891389
rs1441264
rs13329567
rs7599312
rs17066856
rs12940622
rs6804842
rs7550711
rs9579083
rs13078960
rs7903146
rs11165643
rs17381664
rs2836754
rs13130484
rs1000940
rs7715256
rs879620
rs1528435
rs9540493
rs2820292
rs17203016
rs10733682
rs2176598
rs13191362
rs6457796
rs1928295
rs977747
rs4740619
rs7138803
rs13021737
rs2890652
rs17094222
rs2365389
rs10132280
rs14810
rs2033529
rs3800229
rs9304665
rs657452
rs9926784
rs3849570
rs12986742
rs16851483
rs1460676
rs1167827
rs6477694
rs7899106
rs3736485
rs7531118
rs10182181
rs12286929
rs13201877
rs12429545
rs3817334
rs6713510
rs2183825
rs9374842
rs13107325
rs11672660
rs4889606
rs10840100
rs11057405
rs1421085
rs11727676
rs1516725
0.0000 0.0025 0.0050 0.0075
MR leave−one−out sensitivity analysis for
'Body mass index || id:2' on 'Non−cancer illness code  self−reported: gout || id:UKB−a:107'
Appendix 1—figure 8. A plot illustrating a leave-one out analysis between body mass index
and gout.
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